Abstract
Many cartilage tissue engineering approaches aim to differentiate human mesenchymal stem cells (hMSCs) into chondrocytes and develop cartilage in vitro by targeting cell-matrix interactions. We sought to better inform the design of cartilage tissue engineering scaffolds by understanding how integrin expression changes during chondrogenic differentiation. In three models of in vitro chondrogenesis, we studied the temporal change of cartilage phenotype markers and integrin subunits during the differentiation of hMSCs. We found that transcript expression of most subunits was conserved across the chondrogenesis models, but was significantly affected by the time-course of differentiation. In particular, ITGB8 was up-regulated and its importance in chondrogenesis was further established by a knockdown of integrin β8, which resulted in a non-hyaline cartilage phenotype, with no COL2A1 expression detected. In conclusion, we performed a systematic study of the temporal changes of integrin expression during chondrogenic differentiation in multiple chondrogenesis models, and revealed a role for integrin β8 in chondrogenesis. This work enhances our understanding of the changing adhesion requirements of hMSCs during chondrogenic differentiation and underlines the importance of integrins in establishing a cartilage phenotype.
Introduction
Articular hyaline cartilage has a low capacity for self-repair following traumatic injury or degeneration from osteoarthritis, a disease associated with the increasingly ageing population. The extent of endogenous repair is related to the size of the defect and is limited by the avascular nature of cartilage and the low mitotic activity of chondrocytes. For many patients, surgical solutions can reduce pain and swelling and improve joint motility, but the resulting tissue typically resembles fibrocartilage, which is mechanically inferior and less durable than articular cartilage, and tends to be accompanied by an immune response [1]. There is therefore an unquestionable need for regenerative medicine approaches to cartilage repair.
A wide range of tissue engineering strategies have been employed but the paradigm for most involves the combination of cells, a scaffold, and soluble or insoluble cues, many iterations of which have been studied [2]. For the cell source, some success has been achieved using chondrocytes [3], bone marrow-derived mesenchymal stem cells (MSCs) [4,5], adipose-derived stem cells [6], embryonic stem cells [7], and combinations thereof [8]. The use of adult stem cells is inspired by their availability (especially compared to autologous chondrocytes) and their ability to be expanded in vitro. As with the cell source, the scaffold design has been a widely studied variable. Over recent years, there have been a number of successful engineering approaches, mimicking many of the native properties of cartilage, in the hope that the cell phenotype will respond accordingly. For example, the spatially varying mechanical properties of cartilage were mimicked using polymers and hydrogels [9], the nano- to micrometre topography was mimicked with polymer fibres [10,11], and the extracellular matrix (ECM) components of cartilage were preserved through a decellularisation technique [12]. Unfortunately, embryogenesis remains the only reliable means of generating native cartilage, and the best option available to surgeons is a selection of polymer fleeces, sponges, and fibrous materials seeded with the patient’s own stem cells for implantation into the defect site.
The disparity between the promise of tissue engineering and its actual success in replicating chondrogenesis can be explained by many factors. For example, despite many available differentiation protocols, the establishment of phenotypic chondrocytes, capable of producing a cartilage-like ECM, remains a challenge [13]. Indeed, chondrocytes have a tendency to dedifferentiate towards a fibroblastic phenotype in vitro, a phenomenon that has been linked to cell-matrix interactions that become disregulated over time. The importance of the ECM as a survival factor has long been known and has also been demonstrated in the case of chondrocytes [14]. Even on surgical implants, providing the correct matrix cues affects chondrocyte phenotype [15]. However, it has been shown that whilst removing chondrocytes from their native ECM leads to dedifferentiation, providing tissue-specific ECM alone is not enough to maintain the phenotype [16]. This may be because the interaction of cells with their ECM is more than for physical attachment, and rather, it importantly provides a source of sequestered growth factors and signalling initiators, all of which are tightly spatially and temporally regulated.
One of the key families of cell surface receptors involved in cell-ECM interactions is the integrins. They are heterodimeric (one α and one β subunit) transmembrane glycoproteins, consisting of a large globular extracellular domain, capable of specificity to ECM proteins and other cell surface receptors, and a smaller cytoplasmic domain, which interacts with many cytoskeletal proteins and initiates signalling cascades. These interactions are important in chondrocytes and chondrogenesis, as demonstrated in experiments using blocking antibodies. For example, blocking integrin β1 severely interferes with chondrocyte adhesion to fibronectin, type II collagen, and type IV collagen, and inhibits chondrogenesis [17,18]. Integrins are also important in pericellular matrix development and in dedifferentiation, the latter of which can be mitigated by inhibiting the αv or β5 integrin subunits [19,20].
With the importance of cell-ECM and, in particular, integrin-mediated signalling established, we sought to determine the temporal change of integrin expression in different in vitro models of chondrogenesis. Many groups use integrin ligands as a means of promoting cell attachment and differentiation, yet it is unknown how integrin expression changes as MSCs become chondrocytes. We therefore aimed to generate the knowledge necessary to improve the design of tissue engineering scaffolds. We found that integrin expression was generally well-conserved across different models of chondrogenic differentiation, but significantly changed during the time-course of differentiation.
Materials and Methods
Cell culture
Human bone marrow-derived mesenchymal stem cells (hMSCs) from two donors (one 60 year old female, one 68 year old male) were purchased from PromoCell (UK) (CD44/CD105 > 95% positive, CD31/CD45 > 95% negative). Cells were maintained in growth medium (Mesenchymal Stem Cell Growth Medium; PromoCell, UK) at 37°C and 5% CO2. Prior to differentiation experiments, cells were expanded to Passage 4 and lightly trypsinised using the DetachKit (PromoCell, UK) according to the manufacturer’s instructions.
Pellet culture for chondrogenic differentiation
250,000 hMSCs were suspended in 500 μl of either growth or chondrogenic medium (Mesenchymal Stem Cell Chondrogenic Medium; PromoCell, UK) and centrifuged at 450 x g for 10 min in a 15 ml polypropylene conical tube. Cells were maintained at 37°C and 5% CO2 in the conical tubes with loosened caps for gas exchange. Medium was changed every 2-3 days.
Micromass for chondrogenic differentiation
250,000 hMSCs were suspended in 200 μl of growth medium in a 96-well round bottom suspension culture plate (Nunc, UK). After 48 h, spheroids began to form spontaneously and cells were fed with either growth or chondrogenic medium. Medium was changed every 2-3 days.
Type II collagen hydrogels for chondrogenic differentiation
Bovine articular cartilage-derived type II collagen (BD Biosciences, UK) was diluted on ice to a final concentration of 1.5 mg/ml in either growth or chondrogenic medium and 2.5% (v/v) HEPES Buffer. The solution was neutralised (pH 7.4) with NaOH and 250,000 hMSCs were seeded in a 200 μl total volume in a 96-well plate. The hydrogels were incubated for 4-5 h at 37°C and 5% CO2 and then an additional 125 μl of medium was added to each well. Medium was changed every 2-3 days.
Histology
In order to evaluate cell morphology and the establishment of an extracellular matrix rich in sulphated glycosaminoglycans (sGAGs) and collagen, histological staining was performed. After 21 days in culture, the samples were washed in PBS, fixed in 3.7% (w/v) paraformaldehyde, washed thoroughly, and stored at 4°C in PBS until embedding. Paraffin embedded samples were sectioned to 10 μm thickness, dewaxed, and stained with haematoxylin/eosin, Alcian blue, and picrosirius red according to standard methods.
RNA extraction and cDNA synthesis
Cells were washed in PBS and 350 μl RLT supplemented with 1% (v/v) β-mercaptoethanol was added. The samples was vigorously lysed with pipetting and vortexing and stored at -20°C prior to RNA extraction using an RNeasy mini kit (Qiagen, UK) according to the manufacturer’s instructions. RNA quality and quantity were assessed on a NanoDrop 2000c. First-strand cDNA was synthesised using Superscript III First-Strand Synthesis kit (Invitrogen, UK) according to the manufacturer’s instructions. 100 ng total RNA was reverse-transcribed in a 20 μl reaction volume followed by an RNase H treatment. cDNA was diluted in dH2O prior to qPCR.
Quantitative real-time polymerase chain reaction (qPCR)
Quantification of mRNA transcripts from three independent experiments (in technical triplicate) occurred after 1, 2, 4, 7, 14, and 21 days. A day 0 sample, hMSCs prior to trypsinisation, was used to normalise integrin subunit expression. Quantitative PCR was performed in a 10 μl reaction on a Rotorgene 6000 (Qiagen, UK) using a Platinum SYBR Green Supermix-UDG kit (Invitrogen, UK) according to the manufacturer’s instructions. Primer sequences (Table S1) to the phenotype markers and integrin subunits were obtained from PrimerBank (Harvard, USA; http://pga.mgh.harvard.edu/primerbank/), with the exception of primers to ACAN, COL6A1, ITGA4, and ITGA6, which were purchased from Qiagen (Quantitect). Thermocycling was as follows: 50°C for 2 min, 95°C for 2 min, 40 cycles of 95°C for 15 s and 62°C for 30 s, and a high resolution melt curve from 70-95°C. For the Quantitect primers, the annealing temperature was 63°C instead of 62°C. All primers were validated with a standard curve to ensure an efficiency of 0.9-1.0 and amplicons were run on an agarose gel to ensure a single product of the correct size. GAPDH was used as a house-keeping gene (p > 0.7 over the time-course, no significant differences in GAPDH detected by Western blotting). Data for the integrin subunits were plotted as 2-ΔΔCt (i.e.- relative to GAPDH and to hMSCs prior to trypsinisation), except when this value was negative, where they were plotted as -1/2-ΔΔCt. Data for the phenotype markers were plotted as 2-ΔCt (i.e.- relative to GAPDH) because the genes were typically not detected in hMSCs.
shRNA silencing of ITGB8
Lentiviral particles containing shRNA to silence ITGB8 and control (scrambled) shRNA were purchased from Santa Cruz (Germany). Transduction conditions were optimised using Cop-GFP lentiviral particles. hMSCs were seeded in 12-well plates at 6,000 cells/cm2 and grown to 50% confluency. They were transduced with 10 μl/ml virus in 5 μg/ml polybrene in growth medium. After 24 h, the medium was changed and the cells were allowed to recover for a further 24 h. They were then switched to selection medium, containing 4 μg/ml puromycin. After three days, cells were pooled, assayed for transduction efficiency, and cultured under standard growth conditions until differentiation experiments. Differentiation was performed in the micromass model and transcript quantification occurred after 0, 4, 7, and 21 days.
Western blotting of integrin β8
hMSCs were washed in PBS and lysed in RIPA buffer (Sigma, UK) supplemented with protease (Roche, UK) and phosphatase (Sigma, UK) inhibitors. The lysate was clarified by centrifugation at 4°C and total protein was quantified with a Bradford assay (Sigma, UK). 15 μg total protein in Laemmli’s Sample Buffer was loaded on a 10% SDS-PAGE gel. Protein was transferred to a PVDF membrane under wet transfer conditions. The membrane was blocked with 5% (w/v) BSA in TBS/T and incubated in antibodies against integrin β8 (1/200; sc-6638, Santa Cruz, Germany) and GAPDH (1/5000; Clone 2D4A7, Thermo Fisher, UK) overnight at 4°C. After washing, the membrane was incubated in secondary antibodies against IgG (anti-goat 1/5000 and anti-mouse 1/5000; Li-Cor Biosciences, UK) labelled with IRDye. The blot was visualised on an Odyssey CLx with Image Studio software (Li-Cor Biosciences, UK).
Statistical analysis
Student’s t-test and ANOVA were used to determine statistical significance (p < 0.05). Quantitative PCR data are from three independent experiments performed in technical triplicates. Relative expression was calculated using the ΔΔCt method (relative to GAPDH and day 0 hMSCs), and down-regulation is presented as the negative inverse.
Results
Cartilage phenotype markers during chondrogenic differentiation
Before determining the changing integrin expression during chondrogenesis, we sought an appropriate in vitro model that resulted in a high expression of chondrogenic markers and the establishment of a hyaline cartilage-like extracellular matrix (ECM). We therefore used qPCR to characterise three different chondrogenesis models (Figure 1; pellet culture, micromass culture, and a type II collagen hydrogel) for the expression of COL1A1 (type I collagen), COL2A1 (type II collagen), COL6A1 (type VI collagen), COL10A1 (type X collagen), ACAN (aggrecan), HSPG2 (perlecan), RUNX2, and SOX9 (Figures 2-3), and also used histology to view an ECM rich in collagen and sulphated glycosaminoglycans (Figure S1). In all experiments, results are reported as statistically significant when p < 0.05.
Figure 2 demonstrates the temporally changing expression of four types of collagen mRNA in hMSCs cultured in either growth or chondrogenic medium in the three different chondrogenesis models. Only hMSCs cultured in chondrogenic medium expressed COL2A1 (Figure 2A-C). Cells cultured in a micromass had delayed expression of this key marker of articular hyaline cartilage ECM, but a similar level of the transcript was achieved in all models after 21 days. COL6A1, the defining component of the pericellular matrix, was relatively unchanged in hMSCs in a pellet culture or a type II collagen hydrogel (Figure 2D-F). However, in the micromass, it was down-regulated to non-detectable levels after seven days. For COL1A1, there were no significant differences between the chondrogenesis models, but as to be expected, chondrogenic medium resulted in an up-regulation over time (Figure 2G-I). COL10A1 was highly up-regulated over time and to a significantly higher degree in cells in chondrogenic medium (Figure 2J-L), while for this gene, there were no significant differences between the chondrogenesis models.
Figure 3 demonstrates the temporal changes of mRNA expression of four other phenotype markers in hMSCs cultured in either growth or chondrogenic medium in the three different chondrogenesis models. For ACAN, which was only expressed in the presence of chondrogenic medium, there were no significant differences between the chondrogenesis models, except a slight delay of transcript expression in the micromass (Figure 3A-C). HSPG2, the gene encoding perlecan, a component of the pericellular matrix, was unaffected by the chondrogenesis system, but was expressed at significantly higher levels in cells cultured in chondrogenic medium (Figure 3D-F). RUNX2, a transcription factor central in osteogenesis, but with an additional role in chondrogenesis, was highly up-regulated over time in the pellet culture and micromass but was undetectable in the type II collagen hydrogels (Figure 3G-I). SOX9, a transcription factor central but not exclusive to chondrogenesis, was unaffected by either the chondrogenesis model or the medium conditions over time (Figure 3J-L).
hMSCs and chondrocytes express different integrin subunits
In order to determine the differences between integrin subunits expressed in hMSCs and chondrocytes, RNA was isolated from hMSCs in standard culture conditions (48 h after seeding) and from normal human articular chondrocytes (PromoCell HCH Pellet, UK). Figure 4 shows the relative expression of ten α subunits and seven β subunits. ITGA2, ITGA3, ITGA4, ITGA6, ITGA7, ITGA10, ITGB3, and ITGB5 mRNA levels were statistically significantly higher in hMSCs than in chondrocytes. ITGA1, ITGB2, and ITGB8 mRNA levels were statistically significantly higher in chondrocytes than in hMSCs. Expression of ITGA5, ITGA11, ITGAV, and ITGB1 were unchanged between the two cell types. ITGB6 and ITGB7 were not detected in either hMSCs or chondrocytes.
Integrin expression in chondrogenesis
To better understand how the expression of integrin subunits changes during chondrogenic differentiation of hMSCs, a time-course of transcript levels over 21 days was established with qPCR. Figure 5 shows the expression of 14 integrin subunits relative to GAPDH as an internal control and to day 0 hMSCs (prior to trypsinisation).
Three conditions and their effect on integrin expression were studied concurrently: the effect of the culture medium, the effect of the chondrogenesis model, and the effect of the time-course. In general, cells in growth medium (Figure 5A-C) had higher integrin expression than in chondrogenic medium (Figure 5D-F). The medium composition had a significant effect (p < 0.05) on all subunits measured except for ITGA6, ITGA7, and ITGA11 in the pellet culture, ITGA4, ITGA6, ITGA7, ITGA10, and ITGB1 in the micromass culture, and ITGA7 and ITGB1 in the type II collagen hydrogel. In comparing the three chondrogenesis models, integrin subunit expression was also well-conserved. For cells cultured in growth medium, only ITGA7 expression was different (p < 0.05) during the time-course between the different chondrogenesis models. For cells cultured in chondrogenic medium, only ITGA5, ITGA6, and ITGB3 expression were different between the chondrogenesis models. The time-course had the greatest effect on the expression of integrin subunit mRNA. In growth medium, statistically significant up-regulation was observed for ITGA1 (pellet culture and type II collagen hydrogel), ITGA3 (pellet culture and type II collagen hydrogel), ITGA4 (type II collagen hydrogel), ITGA7 (pellet culture), ITGA10 (pellet culture and type II collagen hydrogel), ITGA11 (all chondrogenesis models), ITGAV (all chondrogenesis models), ITGB1 (all chondrogenesis models), ITGB5 (all chondrogenesis models), and ITGB8 (all chondrogenesis models). Down-regulation was not statistically significant for any integrin subunits in hMSCs cultured growth medium. In chondrogenic medium, there was generally less up-regulation of the integrin subunits than in growth medium. Statistically significant up-regulation was observed for ITGA4 (pellet culture), ITGA7 (pellet culture), ITGA11 (all chondrogenesis models), ITGAV (pellet culture), ITGB5 (pellet culture), and ITGB8 (all chondrogenesis models). Statistically significant down-regulation was observed for ITGA2 (micromass), ITGA3 (pellet culture), ITGA5 (all chondrogenesis models), ITGA6 (type II collagen hydrogel), and ITGB3 (all chondrogenesis models).
Knockdown of ITGB8 interferes with chondrogenic phenotype
An shRNA lentiviral construct was used to create a stable knockdown of ITGB8, an integrin subunit known to be involved in the release of insoluble TGF-β from its latency associated peptide and therefore thought to be important in chondrogenic differentiation [21]. Our first experiments had demonstrated that it was one of the few integrin subunits consistently up-regulated in chondrogenic differentiation regardless of the medium composition or the chondrogenesis model. Figure 6A depicts the knockdown efficiency before and after puromycin selection. After selection, quantitative PCR showed a silencing efficiency of 89% and the protein was undetectable by Western blotting (Figure 6B). Following expansion, the cells were differentiated in the micromass model of chondrogenesis.
Integrin subunit expression during chondrogenic differentiation was generally unaffected in the integrin β8 knockdown compared to the wildtype (Figures S9-S11). After 21 days, there were no statistically significant differences in the α subunits. The β subunits were more affected, with ITGB3 expression undetectable after four days. Interestingly, many integrin subunits were up-regulated in the integrin β8 knockdown hMSCs at day 0 (prior to formation of the micromass). This effect was statistically significant for ITGA3, ITGA4, ITGA6, ITGA7, ITGA11, ITGAV, ITGB1, and ITGB5 (all up-regulated in the ITGB8 knockdown), and ITGA5 (down-regulated in the ITGB8 knockdown).
All phenotype markers were affected by knocking down integrin β8 (Figure 6C-J). ACAN was still only expressed in chondrogenic medium, but it was significantly down-regulated in the knockdown after 4 days compared to wildtype hMSCs. COL2A1 expression had a striking change in the integrin β8 knockdown, where it was not detected at any point. The two pericellular matrix markers, COL6A1 and HSPG2, were significantly up-regulated compared to wildtype in both growth and chondrogenic medium, with a greater up-regulation observed in growth medium. COL1A1 was significantly down-regulated in chondrogenic medium after 21 days but was unaffected in growth medium. COL10A1 was down-regulated compared to the wildtype in growth medium at day 7, but was expressed similarly by day 21. In chondrogenic medium, it was unaffected by the knockdown of integrin β8. RUNX2 expression was abolished by knocking down integrin β8 in both growth and chondrogenic medium at all time points. SOX9 was significantly down-regulated after 21 days in chondrogenic medium but was unaffected in growth medium.
Discussion
Tissue engineering strategies offer a promising treatment for diseased or damaged cartilage. However, they have so far failed to deliver on this promise, and scaffolds are frequently marred by their inability to support initial hMSC attachment and subsequent differentiation into chondrocytes. Our aim was to develop a better understanding of the changing integrin expression during chondrogenic differentiation. This could lead to an improved scaffold design, incorporating the ligands required to promote initial attachment and drive chondrogenic signalling to ultimately create a therapeutically useful cartilage construct. We used qPCR and the in vitro chondrogenic differentiation models commonly used in cartilage tissue engineering to ensure our results were translatable to other studies. We showed how integrin transcript expression changes during chondrogenic differentiation of hMSCs in three chondrogenesis models and found a new role for integrin β8 in the establishment of a chondrogenic phenotype.
We began by examining the expression of key phenotype markers in hMSCs undergoing chondrogenic differentiation in three relevant in vitro models. We found that the phenotype markers were remarkably well-conserved in the three models, with only COL6A1 and RUNX2 differentially expressed. The disruption of RUNX2, as seen in the type II collagen hydrogel, has been shown to block chondrocyte hypertrophy and the progression of osteoarthritis [22]. Two commonly used indicators of articular cartilage phenotype, the COL2A1/COL1A1 and COL2A1/COL10A1 ratios, were statistically similar (p > 0.05) in the different chondrogenesis models at all time points. We then quantified the changing integrin expression of hMSCs undergoing chondrogenesis. While the 21 day time-course was not long enough to produce mature cartilage, the trends of the integrin transcript expression we measured in differentiating hMSCs were in agreement with the expression we found in cells derived from healthy human articular cartilage. Generally, we found that integrin expression was higher in cells cultured in growth medium than in chondrogenic medium and, like the phenotype markers, was widely conserved across the chondrogenesis models. The most striking changes were in the changing expression over the 21 day time-course. The hMSCs had significantly changing transcript expression for most integrins, which should come as no surprise, given the role integrins play in virtually every aspect of development.
While this is one of the most extensive studies quantifying changing integrin expression in multiple chondrogenesis models over a 21 day time-course, it is by no means the first example of integrins and integrin ligands affecting MSCs and chondrogenesis. The expression of a number of cell surface receptors has been previously reported in MSCs [23]. Some studies have looked at changing integrin expression in chondrogenesis and in dedifferentiation of chondrocytes [24,25]. For example, the β1 and α3 subunits have been implicated in dedifferentiation, followed by an increase of fibronectin in the ECM [26]. Cartilage sections have also been stained for integrins. It has been reported that the most abundant integrin in chondrocytes is α5β1 [18], and that only αv is differentially expressed in the different cartilage zones [27,28]. Our results are in line with many of the studies examining specific integrin expression. For example, integrin α1 was previously detected in human articular cartilage, while integrin α3 was not [27]. We observed up-regulation of ITGA1 and down-regulation of ITGA3 in chondrogenesis, in agreement with this result.
ITGB8 was one of the only integrin subunits consistently up-regulated in all chondrogenesis models in this study. Given its known role in the mechanical and proteolytic release of TGF-β from its latency complex [21], we sought to demonstrate its role in chondrogenesis. An 89% mRNA knockdown led to non-detectable expression of COL2A1, the defining marker of hyaline cartilage, demonstrating the importance of this integrin in the chondrogenic differentiation of hMSCs. It also resulted in an up-regulation of the pericellular matrix markers COL6A1 and HSPG2, and in both cases, this increase was more pronounced in growth medium than in chondrogenic medium. How this integrin β8 knockdown is affecting TGF-β signalling remains to be seen, but it may have to do with the source of TGF-β. There is some evidence that while TGF-β3 has a positive effect, TGF-β1 signalling may suppress chondrogenic differentiation [29]. The integrin αvβ8 knockdown would have diminished the ability of the cell to activate insoluble (cell-secreted) TGF-β but would not have necessarily interfered with its binding of the soluble (medium supplemented, TGF-β3) form of the growth factor. This could at least partially explain why the effects of the knockdown of integrin β8 on cell phenotype were affected by the medium composition. Future work could include characterising the effect of the TGF-β isoforms on integrin αvβ8-mediated signalling in chondrogenic differentiation.
A number of studies have demonstrated that incorporating integrin ligands in a scaffold can influence cell behaviour. For example, IKVAV, a laminin-derived integrin ligand, has been shown to support hMSC viability [30]. In our experiments, we found that ITGA3 and ITGA6, which are known to heterodimerise with ITGB1 (along with ITGB4 in the case of ITGA6) to bind laminin, were typically down-regulated in chondrogenic differentiation. This agrees with the finding that hMSCs can be supported by IKVAV but suggests that chondrocytes will not. As a second example, when GFOGER, a collagen mimetic peptide capable of binding cells via β1 integrins was incorporated in poly(ethylene glycol) (PEG) hydrogels, hMSCs underwent chondrogenic differentiation to a greater extent than in the hydrogels alone [31]. This is also in agreement with our results, which found relatively constant expression of the collagen-binding integrins, suggesting both hMSCs and chondrocytes would respond well to extracellular collagen. Finally, fibronectin and its peptide derivatives are frequently used to improve stable cell adhesion though some studies demonstrate a negative effect on chondrogenesis when RGD is incorporated in scaffolds [32,33]. In this study, we found some of the fibronectin-binding integrins (in particular, ITGAV) maintained relatively constant expression during chondrogenesis. The presence of these receptors indicates that both hMSCs and chondrocytes might maintain their phenotype in the presence of fibronectin. This is reasonable, considering fibronectin is present in the ECM throughout differentiation and in mature chondrocytes [34]. It would be of particular interest to cater to the temporally changing integrin expression to guide stem cells to become chondrocytes. Integrin ligands, catering to the temporally changing integrin expression determined in this study, could be incorporated in tissue engineering scaffolds to influence cell behaviour. This concept has been attempted in adipogenesis and osteogenesis, but experiments targeting specific integrins in chondrogenesis have thus far primarily focused on preventing dedifferentiation of mature chondrocytes [35].
Conclusion
In conclusion, we have completed a characterisation of integrin expression in three in vitro chondrogenesis models.
We found that integrin expression generally decreased in chondrogenic differentiation and that the expression of most subunits was temporally regulated. We further examined the role for integrin β8 and found that its knockdown resulted in an up-regulation of pericellular matrix synthesis and an elimination of COL2A1 expression. Having studied integrin expression in multiple chondrogenesis models and demonstrated a role for integrin β8 in chondrogenesis, this study has improved our understanding of integrin expression in chondrogenic differentiation and the role of the ECM in influencing cell behaviour. It can inform the future design of tissue engineering scaffolds to include ligands to cater to the changing adhesion requirements of hMSCs in chondrogenic differentiation.
Supporting Information
Funding Statement
MMS thanks the Medical Engineering Solutions in Osteoarthritis Centre of Excellence funded by the Wellcome Trust and the Engineering and Physical Sciences Research Council, and MMS and VL thank the Rosetrees Trust for financial support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Revell CM, Athanasiou KA (2009) Success rates and immunologic responses of autogenic, allogenic, and xenogenic treatments to repair articular cartilage defects. Tissue Eng Part B Rev 15: 1–15. doi: 10.1089/ten.teb.2008.0189. PubMed: 19063664. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Mahmoudifar N, Doran PM (2012) Chondrogenesis and cartilage tissue engineering: the longer road to technology development. Trends Biotechnol 30: 1–11. PubMed: 22071143. [DOI] [PubMed] [Google Scholar]
- 3. Pabbruwe MB, Esfandiari E, Kafienah W, Tarlton JF, Hollander AP (2009) Induction of cartilage integration by a chondrocyte/collagen-scaffold implant. Biomaterials 30: 4277–4286. doi: 10.1016/j.biomaterials.2009.02.052. PubMed: 19539365. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Li W-J, Tuli R, Okafor C, Derfoul A, Danielson KG et al. (2005) A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. Biomaterials 26: 599–609. doi: 10.1016/j.biomaterials.2004.03.005. PubMed: 15282138. [DOI] [PubMed] [Google Scholar]
- 5. Pabbruwe MB, Kafienah W, Tarlton JF, Mistry S, Fox DJ, Hollander AP (2010) Repair of meniscal cartilage white zone tears using a stem cell/collagen-scaffold implant. Biomaterials 31: 2583–2591. doi: 10.1016/j.biomaterials.2009.12.023. PubMed: 20053438. [DOI] [PubMed] [Google Scholar]
- 6. Dragoo JL, Carlson G, McCormick F, Khan-Farooqi H, Zhu M et al. (2007) Healing full-thickness cartilage defects using adipose-derived stem cells. Tissue Eng 13: 1615–1621. doi: 10.1089/ten.2006.0249. PubMed: 17518742. [DOI] [PubMed] [Google Scholar]
- 7. Vats A, Bielby RC, Tolley N, Dickinson SC, Boccaccini AR et al. (2006) Chondrogenic differentiation of human embryonic stem cells: the effect of the micro-environment. Tissue Eng 12: 1687–1697. doi: 10.1089/ten.2006.12.1687. PubMed: 16846363. [DOI] [PubMed] [Google Scholar]
- 8. Bian L, Zhai DY, Mauck RL, Burdick JA (2011) Coculture of human mesenchymal stem cells and articular chondrocytes reduces hypertrophy and enhances functional properties of engineered cartilage. Tissue Eng Part A 17: 1137–1145. doi: 10.1089/ten.tea.2010.0531. PubMed: 21142648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9. Nguyen LH, Kudva AK, Saxena NS, Roy K (2011) Engineering articular cartilage with spatially-varying matrix composition and mechanical properties from a single stem cell population using a multi-layered hydrogel. Biomaterials 32: 6946–6952. doi: 10.1016/j.biomaterials.2011.06.014. PubMed: 21723599. [DOI] [PubMed] [Google Scholar]
- 10. Coburn JM, Gibson M, Monagle S, Patterson Z, Elisseeff JH (2012) Bioinspired nanofibers support chondrogenesis for articular cartilage repair. Proc Natl Acad Sci U S A 109: 10012–10017. doi: 10.1073/pnas.1121605109. PubMed: 22665791. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. McCullen SD, Autefage H, Callanan A, Gentleman E, Stevens MM (2012) Anisotropic fibrous scaffolds for articular cartilage regeneration. Tissue Eng Part A 18: 2073–2083. doi: 10.1089/ten.tea.2011.0606. PubMed: 22655795. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Xue JX, Gong YY, Zhou GD, Liu W, Cao Y, Zhang WJ (2012) Chondrogenic differentiation of bone marrow-derived mesenchymal stem cells induced by acellular cartilage sheets. Biomaterials 33: 5832–5840. doi: 10.1016/j.biomaterials.2012.04.054. PubMed: 22608213. [DOI] [PubMed] [Google Scholar]
- 13. Oldershaw RA, Baxter MA, Lowe ET, Bates N, Grady LM et al. (2010) Directed differentiation of human embryonic stem cells toward chondrocytes. Nat Biotechnol 28: 1187–1194. doi: 10.1038/nbt.1683. PubMed: 20967028. [DOI] [PubMed] [Google Scholar]
- 14. Hirsch MS, Lunsford LE, Trinkaus-Randall V, Svoboda KK (1997) Chondrocyte survival and differentiation in situ are integrin mediated. Dev Dyn 210: 249–263. doi: 10.1002/(SICI)1097-0177(199711)210:3. PubMed: 9389451. [DOI] [PubMed] [Google Scholar]
- 15. Albrecht C, Tichy B, Nürnberger S, Hosiner S, Zak L et al. (2011) Gene expression and cell differentiation in matrix-associated chondrocyte transplantation grafts: a comparative study. Osteoarthr Cartilage 19: 1219–1227. doi: 10.1016/j.joca.2011.07.004. [DOI] [PubMed] [Google Scholar]
- 16. Brodkin KR, García AJ, Levenston ME (2004) Chondrocyte phenotypes on different extracellular matrix monolayers. Biomaterials 25: 5929–5938. doi: 10.1016/j.biomaterials.2004.01.044. PubMed: 15183607. [DOI] [PubMed] [Google Scholar]
- 17. Loeser RF (1993) Integrin-mediated attachment of articular chondrocytes to extracellular matrix proteins. Arthritis Rheum 36: 1103–1110. doi: 10.1002/art.1780360811. PubMed: 8343186. [DOI] [PubMed] [Google Scholar]
- 18. Shakibaei M (1998) Inhibition of chondrogenesis by integrin antibody in vitro. Exp Cell Res 240: 95–106. doi: 10.1006/excr.1998.3933. PubMed: 9570925. [DOI] [PubMed] [Google Scholar]
- 19. Knudson CB (1993) Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix. J Cell Biol 120: 825–834. doi: 10.1083/jcb.120.3.825. PubMed: 7678838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Fukui N, Ikeda Y, Tanaka N, Wake M, Yamaguchi T et al. (2011) αvβ5 integrin promotes dedifferentiation of monolayer-cultured articular chondrocytes. Arthritis Rheum 63: 1938–1949. doi: 10.1002/art.30351. PubMed: 21425129. [DOI] [PubMed] [Google Scholar]
- 21. Wipff P-J, Hinz B (2008) Integrins and the activation of latent transforming growth factor β1 - an intimate relationship. Eur J Cell Biol 87: 601–615. doi: 10.1016/j.ejcb.2008.01.012. PubMed: 18342983. [DOI] [PubMed] [Google Scholar]
- 22. Kamekura S, Kawasaki Y, Hoshi K, Shimoaka T, Chikuda H et al. (2006) Contribution of runt-related transcription factor 2 to the pathogenesis of osteoarthritis in mice after induction of knee joint instability. Arthritis Rheum 54(8): 2462–2470. doi: 10.1002/art.22041. PubMed: 16868966. [DOI] [PubMed] [Google Scholar]
- 23. Varas L, Ohlsson LB, Honeth G, Olsson A, Bengtsson T et al. (2007) α10 integrin expression is up-regulated on fibroblast growth factor-2-treated mesenchymal stem cells with improved chondrogenic differentiation potential. Stem Cells Dev 16: 965–978. doi: 10.1089/scd.2007.0049. PubMed: 18047418. [DOI] [PubMed] [Google Scholar]
- 24. Shakibaei M, Zimmermann B, Merker HJ (1995) Changes in integrin expression during chondrogenesis in vitro: an immunomorphological study. J Histochem Cytochem 43: 1061–1069. doi: 10.1177/43.10.7560884. PubMed: 7560884. [DOI] [PubMed] [Google Scholar]
- 25. Tavella S, Bellese G, Castagnola P, Martin I, Piccini D et al. (1997) Regulated expression of fibronectin, laminin and related integrin receptors during the early chondrocyte differentiation. J Cell Sci 110: 2261–2270. PubMed: 9378775. [DOI] [PubMed] [Google Scholar]
- 26. Goessler UR, Bieback K, Bugert P, Heller T, Sadick H et al. (2006) In vitro analysis of integrin expression during chondrogenic differentiation of mesenchymal stem cells and chondrocytes upon dedifferentiation in cell culture. Int J Mol Med 17: 301–307. PubMed: 16391830. [PubMed] [Google Scholar]
- 27. Woods VL Jr, Schreck PJ, Gesink DS (1994) Integrin expression by human articular chondrocytes. Arthritis Rheum 37: 537–544. doi: 10.1002/art.1780370414. PubMed: 8147931. [DOI] [PubMed] [Google Scholar]
- 28. Ostergaard K, Salter DM, Petersen J, Bendtzen K, Hvolris J, Andersen CB (1998) Expression of α and β subunits of the integrin superfamily in articular cartilage from macroscopically normal and osteoarthritic human femoral heads. Ann Rheum Dis 57: 303–308. doi: 10.1136/ard.57.5.303. PubMed: 9741315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29. Yang Z, Shi Y, Wei X, He J, Yang S et al. (2010) Fabrication and repair of cartilage defects with a novel acellular cartilage matrix scaffold. Tissue Eng Part C Methods 16: 865–876. doi: 10.1089/ten.tec.2009.0444. PubMed: 19891538. [DOI] [PubMed] [Google Scholar]
- 30. Jongpaiboonkit L, King WJ, Murphy WL (2009) Screening for 3D environments that support human mesenchymal stem cell viability using hydrogel arrays. Tissue Eng Part A 15: 343–353. doi: 10.1089/ten.tea.2008.0096. PubMed: 18759676. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Liu SQ, Tian Q, Hedrick JL, Po Hui JH, Ee PLR, Yang YY (2010) Biomimetic hydrogels for chondrogenic differentiation of human mesenchymal stem cells to neocartilage. Biomaterials 31: 7298–7307. doi: 10.1016/j.biomaterials.2010.06.001. PubMed: 20615545. [DOI] [PubMed] [Google Scholar]
- 32. Connelly JT, García AJ, Levenston ME (2008) Interactions between integrin ligand density and cytoskeletal integrity regulate BMSC chondrogenesis. J Cell Physiol 217: 145–154. doi: 10.1002/jcp.21484. PubMed: 18452154. [DOI] [PubMed] [Google Scholar]
- 33. Connelly JT, García AJ, Levenston ME (2007) Inhibition of in vitro chondrogenesis in RGD-modified three-dimensional alginate gels. Biomaterials 28: 1071–1083. doi: 10.1016/j.biomaterials.2006.10.006. PubMed: 17123602. [DOI] [PubMed] [Google Scholar]
- 34. Singh P, Schwarzbauer JE (2012) Fibronectin and stem cell differentiation - lessons from chondrogenesis. J Cell Sci 125: 3703–3712. doi: 10.1242/jcs.095786. PubMed: 22976308. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Frith JE, Mills RJ, Hudson JE, Cooper-White JJ (2012) Tailored integrin-extracellular matrix interactions to direct human mesenchymal stem cell differentiation. Stem Cells Dev 21: 2442–2456. doi: 10.1089/scd.2011.0615. PubMed: 22455378. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.